Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 2
4(66.7%)
Phase 1
2(33.3%)
6Total
Phase 2(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03970447Phase 2Recruiting

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Role: collaborator

NCT06285214Phase 1Completed

Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome

Role: lead

NCT06545916Phase 2Active Not Recruiting

Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder

Role: lead

NCT06545929Phase 2Completed

Study of Sunobinop on Craving in Alcohol Use Disorder

Role: lead

NCT06024642Phase 1Completed

Study of V117957 in Overactive Bladder Syndrome

Role: lead

NCT04035200Phase 2Completed

Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation

Role: lead

All 6 trials loaded